Accordingly, a phase I clinical trial employing autologous CD34+ cell to treated patients with CKD stages III and IV was performed with two essential purposes as: (1) to investigate the safety of autologous administration of peripheral blood-derived CD34+ cells to CKD patients, and (2) to analyze endothelial dysfunction elements, focusing on the angiogenesis (i.e., by Matrigel assay) and circulating anti-apoptotic micro-RNAs. The gene discussed is CD34; the disease is chronic kidney disease.